SAN FRANCISCO, November 7, 2016 /PRNewswire/ --
The Pulmonary Arterial Hypertension (PAH) market is expectedto reach USD 8.7 billion by 2025, according to the new report by Grand View Research, Inc. Incidents of PAH, increasing geriatric population, and government support to develop orphan drugs are key driving factors. Cumulatively,
(Logo: http://photos.prnewswire.com/prnh/20150105/723757 )
The presence of a large population over 60 years globally, which has lower immunity levels and is prone to PAH and associated diseases, which is a high impact-rendering driver for the growth of the market over the forecast period.
Supportive government initiatives for the development of drugs for rare diseases or orphan drugs are anticipated to facilitate the market growth over the forecast period. For instance, the Orphan Drug Act (ODA) 1983, and Rare Disease Act 2002 in the U.S. offer incentives such as tax credits for the development of orphan drugs.
Patent expiry of key PAH molecules is projected to have a deep impact on market dynamics. In coming two to four years the exclusivity of key brands such as Tracleer, Remodulin, Adcirca, Ventavis, Tyvaso, and Letairis will be lost. This will foster the entry of generic product at prices much lower than branded drugs.
Browse full research report with TOC on "Pulmonary Arterial Hypertension (PAH) Market by Drug Class (Prostacyclin and Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators, Endothelin Receptor Antagonists (ERA), Phosphodiesterase 5 (PDE-5)) and Segment Forecasts to 2025" at: http://www.grandviewresearch.com/industry-analysis/pulmonary-arterial-hypertension-market
Further Key Findings From the Study Suggest:
Browse related reports by Grand View Research:
Grand View Research has segmented the PAH market on the basis of drug class and region:
Access research insight: http://www.grandviewresearch.com/research-insights/pulmonary-arterial-hypertension-pah-market-insights-size-share-analysis-report
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Read Our Blogs -grandviewresearch.com/blogs/healthcare
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: firstname.lastname@example.org
SOURCE Grand View Research, Inc.
Subscribe to our Free Newsletters!